Stay updated on Pembrolizumab Combo in ES-SCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Combo in ES-SCLC Clinical Trial page.

Latest updates to the Pembrolizumab Combo in ES-SCLC Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedLocations section updated with numerous new trial sites across the US and internationally, including multiple states and countries. Several previously listed sites have been removed.SummaryDifference2%

- Check19 days agoNo Change Detected
- Check26 days agoNo Change Detected
- Check40 days agoChange DetectedThe page revision label was updated from v3.2.0 to v3.3.2, indicating a minor metadata update.SummaryDifference0.0%

- Check48 days agoChange DetectedRemoved the government funding lapse notice; no study content or endpoints were changed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check69 days agoChange DetectedThe two screenshots show no substantive changes to the study details, eligibility criteria, endpoints, or locations; any differences appear to be minor formatting or wording adjustments that do not affect the page's purpose. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check91 days agoChange DetectedCore content updated with an operating-status notice and a new version (v3.2.0); a specific resource (Small cell lung carcinoma) was removed (v3.1.0).SummaryDifference2%

- Check98 days agoChange DetectedThe page update adds the new version tag v3.1.0 and removes the old v3.0.2 tag, signaling a software version upgrade.SummaryDifference0.0%

Stay in the know with updates to Pembrolizumab Combo in ES-SCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo in ES-SCLC Clinical Trial page.